Hansa Biopharma AB

Hansa Biopharma operates with a capital structure that is highly leveraged and liquidity-constrained. The company reported negative equity of -88.99 million SEK and a debt-to-equity ratio of -10.55, indicating that liabilities significantly exceed equity. The current ratio of 1.94 suggests the company has sufficient current assets to cover current liabilities, but the negative net cash position after subtracting total debt raises concerns about short-term liquidity. Free cash flow was -495.35 million SEK, and operating cash flow was -549.17 million SEK, reflecting ongoing cash outflows from operations.

Profitability metrics are weak, with a net loss of 534.11 million SEK and an operating loss of 580.16 million SEK. Return on equity (ROE) was 6.00%, but this is misleading due to the negative equity base. Return on assets (ROA) was -0.46%, indicating that the company is not generating returns from its asset base. Gross profit of 138.71 million SEK was insufficient to cover operating expenses, highlighting the high cost structure of the business.

The company's revenue is concentrated in a single therapeutic area, with no disclosed geographic diversification in the financial snapshot. This lack of diversification increases exposure to market-specific risks, such as regulatory changes or reimbursement pressures in key markets.

Growth trajectory is uncertain, with no revenue growth data provided in the financial snapshot. The company is in a development phase, and its future revenue will depend on the commercial success of Tovaxin and the approval of new products. Analysts have provided a wide range of price targets, from 35.00 SEK to 103.00 SEK, with a mean of 74.88 SEK and a median of 80.00 SEK, indicating a mixed outlook.

Risk factors include liquidity constraints, with the company reporting negative net cash after subtracting total debt. The risk assessment indicates medium liquidity risk and low dilution risk, but the negative equity and high debt levels suggest potential for future dilution if the company requires additional capital. No dilution sources were identified in the provided data, but the company may face pressure to raise capital in the near term.

Recent events include the continued development of Tovaxin and ongoing clinical trials, but no specific filings or transcripts were provided in the input data to detail recent corporate actions or strategic shifts.